The Clinical investigational site market continues to get more interesting by the day. Private equity-backed Velocity Clinical Research, led by industry veteran Paul Evans, acquired more regional clinical sites, adding six of them while in the process, expanding its footprint to 10 sites in seven states. The company is executing to a strategic vision for a high impact, scaled out clinical investigational site operation that over time could rival some contract research organizations.
Emergence of a New Kind of Site?
Clinical investigational site growth and consolidation takes different forms. Some research sites seek scale via partnerships and alliances—a networked approach with separate ownership—however there could be some operational and scalability challenges with this approach in addition to the potential positive elements.
Other sites, owned and operated by physicians, are raising private equity to grow via opportunistic models—focusing on organic expansion by therapeutic area for diversification, for example. Some of these organizations may not possess deep contract research organizational experience and pedigree.
Based on our re...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).